Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for autoimmune, ...
Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, ...
Vividion publishes manuscript detailing the discovery and optimization of VVD-214, the companyās covalent inhibitor of WRN.
LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSĪ² Unique mechanism of action with potential to slow or stop the progression of HD Cambridge, ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...
Chacko, M.D., chief executive officer, will present a company overview at the 44 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:45 a.m. PT. A live webcast of the ...
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026Planned milestones include pivotal dose selection, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback